Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.
about
T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccinesGenetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidateConstruction of transgenic Plasmodium berghei as a model for evaluation of blood-stage vaccine candidate of Plasmodium falciparum chimeric protein 2.9.Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria.Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvantsEfficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.Rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits Plasmodium falciparum growth in vitroImproved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.Construction of a tetR-integrated Salmonella enterica serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of Plasmodium falciparum for applications in human Vaccine productionNon-variant specific antibody responses to the C-terminal region of merozoite surface protein-1 of Plasmodium falciparum (PfMSP-1(19)) in Iranians exposed to unstable malaria transmission.Total immunoglobulin G and IgG1 subclass levels specific for the MSP-1(19) of Plasmodium falciparum are different in individuals with either processing-inhibitory, blocking or neutral antibodiesVaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malariaProgress toward a malaria vaccine: efficient induction of protective anti-malaria immunity.Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.Towards a blood-stage vaccine for malaria: are we following all the leads?Immunity to asexual blood stage malaria and vaccine approaches.Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malariaBiochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1.Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines.Splenic architecture disruption and parasite-induced splenocyte activation and anergy in Plasmodium falciparum-infected Saimiri sciureus monkeys.Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodiesCpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccineAnalysis of a Multi-component Multi-stage Malaria Vaccine Candidate--Tackling the Cocktail ChallengeMalaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria.Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environmentThe oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria.Effect of Plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine.Effect of GPI anchor moiety on the immunogenicity of DNA plasmids encoding the 19-kDa C-terminal portion of Plasmodium falciparum MSP-1.Cellular responses to modified Plasmodium falciparum MSP119 antigens in individuals previously exposed to natural malaria infection.Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia.Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels.In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
P2860
Q28740432-C14B558A-1714-446E-956B-A304F10D5C73Q28748331-43172B41-FD5E-455B-905C-2A2B75DEA27FQ33499694-F85E4B15-A189-4150-97CB-C704CDBB741EQ33613937-1E7D9E53-FB24-43A8-A040-DD748EA0E5BEQ33772752-11113730-875D-4CD0-96CF-16B1C49087A4Q33858812-0267BA24-F86A-44ED-84A2-AFCBBCE4A7DAQ34006332-F020BAA5-8A25-4E8D-AA7A-55BEE0CF094EQ34006980-0CCDEB55-A79F-458C-8AAE-84779E26E829Q34118325-C60056CB-8247-4E30-B38A-802A4D7721F1Q34120959-3D5FAB2F-6269-43FE-A671-524DA400EBCEQ34154429-AB4458B0-F225-49E8-9342-446E92224EA8Q34206438-06CBE8E3-4B46-4445-A42E-BE0462ECC2B1Q34260722-A344D77A-1325-4016-87BE-E9FE22C3F55EQ34280935-72710AC5-05A4-4735-A523-B0CA0988D38EQ34334187-03B9541A-01CE-4647-B4D5-9DE27A7A7141Q34572160-0256BFC2-8933-467D-A161-75FE96366E5FQ34842236-F9D4BA29-A6BE-41A8-9895-640008F78CCCQ34855814-AF924A00-27DB-4F03-898E-AA9749AC3C86Q34940333-8C2557A1-FB81-4661-8093-3BACD9A3ED4AQ34975629-B09A7D84-4C30-4E0B-A34E-D6AF5F766C86Q35010158-E142BAEA-BEB9-46E1-95AA-27D44C86D7F9Q35226199-CAC26D06-2CBB-443C-B958-1771DE5855B8Q35456892-FC24D0A4-22D8-4186-8771-ADB4BA71815AQ35550770-6316E9E4-FD3D-4E7D-90EF-73A906C4D663Q35683366-32276F39-6D5D-4C69-8F9D-535211781DFEQ36313955-E2E5595D-B2B3-4DE5-9BCD-E3ADF4DC6346Q36368911-4EFEB4C6-13F5-4493-B294-58590D5B10BAQ36615170-27DDF573-0D48-4A92-A2BD-127A104366E7Q36766169-E7392E01-3768-44F1-A320-7241BCCE1D54Q36804322-49B094C3-6E46-43C9-8C6F-0FDB40F3A690Q37075496-A7D9A7C7-7900-47FB-9C2C-D55C6C0DF5BEQ37239807-A2115653-A1DA-4435-97B1-B003BD2C903FQ37448753-A08B568F-4253-40EA-A01D-E708A2472294Q37452080-04299E00-6B72-4BE5-830F-8D0040D1F0E3Q37523653-3E238B2D-FD0C-44CD-9AD0-54E1CE648672Q37523989-C9DA59C8-2CBC-4F3E-AB50-039F2A09B17DQ38882265-4217E45A-0E20-48C1-8FF9-4E3A3E6DCCDAQ39655089-FE1CCA87-6750-417F-AAC3-BCD4154F0D76Q42415030-085A4688-B8C9-42D1-ABFE-3CE822D4C4B6Q42913357-7BF64AAA-EA38-41B5-889A-6A794D3BBCFE
P2860
Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Immunogenicity and efficacy in ...... f merozoite surface protein 1.
@ast
Immunogenicity and efficacy in ...... f merozoite surface protein 1.
@en
Immunogenicity and efficacy in ...... f merozoite surface protein 1.
@nl
type
label
Immunogenicity and efficacy in ...... f merozoite surface protein 1.
@ast
Immunogenicity and efficacy in ...... f merozoite surface protein 1.
@en
Immunogenicity and efficacy in ...... f merozoite surface protein 1.
@nl
prefLabel
Immunogenicity and efficacy in ...... f merozoite surface protein 1.
@ast
Immunogenicity and efficacy in ...... f merozoite surface protein 1.
@en
Immunogenicity and efficacy in ...... f merozoite surface protein 1.
@nl
P2093
P2860
P1476
Immunogenicity and efficacy in ...... f merozoite surface protein 1.
@en
P2093
Blackman MJ
Guevara Patino JA
P2860
P304
P356
10.1128/IAI.68.4.2215-2223.2000
P407
P577
2000-04-01T00:00:00Z